文献速递治疗药物监测与药物基因组学特殊人群用药

以药物公平视角推进CYP2D6药物基因组学

Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens.
PubMed 文献 · Clin Pharmacol Ther · 2023-04-11

综述指出美国FDA批准药物中超过20%经CYP2D6代谢,该基因高度多态且影响阿片类和抗抑郁药等常用药物反应。临床指南推荐根据CYP2D6基因型推断的表型调整治疗方案,但非欧洲人群数据匮乏,欧洲人群结果不能简单外推。文章从药物公平视角强调需加强祖先多样性纳入以优化全球人群药物治疗。

要点

  • FDA批准药物中超过20%经CYP2D6代谢,基因变异影响阿片类和抗抑郁药等反应。
  • 临床指南推荐根据CYP2D6基因型推断的表型调整治疗方案。
  • 非欧洲人群CYP2D6数据匮乏,欧洲人群结果不能简单外推,甚至可能造成伤害。

核心结论

  • CYP2D6药物基因组学需通过药物公平视角加强祖先多样性研究以优化全球人群药物治疗。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 美国FDA批准药物中超过20%经CYP2D6代谢。
  • CYP2D6基因高度多态,遗传变异影响阿片类和抗抑郁药等常用药物反应。
  • 许多等位基因变异或星号等位基因主要见于特定祖先人群,非欧洲人群信息匮乏。
  • 欧洲人群结果不能简单外推到其他群体,某些情况下甚至可能造成伤害。

关键数值与推荐

  • 临床指南目前推荐根据CYP2D6基因型推断的表型调整治疗方案。

临床怎么用

  • 对使用经CYP2D6代谢药物(如阿片类和抗抑郁药)的患者,应了解其CYP2D6代谢者状态以优化治疗结局。
  • 临床CYP2D6药物遗传学检测正被越来越多健康中心实施。

局限性

  • 许多非欧洲人群的CYP2D6遗传变异信息仍然匮乏。
  • 欧洲人群药物遗传学研究结果不能简单外推到其他群体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over 20% of US Food and Drug Administration (FDA)-approved drugs in the United States are metabolized by the hepatic enzyme cytochrome P450 2D6 (CYP2D6). The gene encoding CYP2D6 is highly polymorphic and genetic variation has been shown to impact drug response for many commonly dispensed drugs including opioids and antidepressants. Thus, it is important to understand an individual's CYP2D6 metabolizer status to optimize treatment outcomes for patients taking medications that are metabolized by this enzyme. Consequently, clinical CYP2D6 pharmacogenetic testing is being implemented by a growing number of health centers. Furthermore, clinical guidelines currently recommend adapting therapeutic regimens based on CYP2D6 genotype-informed phenotype. However, CYP2D6 genetic variation varies considerably across global populations and many allelic variants, or star alleles, are predominantly found in certain ancestral populations. Although CYP2D6 genetic variation has been extensively studied, there is still a paucity of information for many non-European populations. As has been shown for other pharmacogenes in randomized controlled trials, results from European populations cannot simply be extrapolated to other groups and, in some cases, even has the potential to cause harm. Therefore, enhanced inclusion in pharmacogenetic studies is urgently needed to increase ancestral representation, determine the extent of global CYP2D6 genetic variation (e.g., ancestry-specific variants), and determine the clinical impact of this variation on clinical treatment outcome. This review highlights knowledge gaps, challenges, and future directions in CYP2D6 pharmacogenomics through a unique pharmacoequity lens to address health inequities that hamper our ability to optimize drug therapy for improved pharmacological outcomes in diverse populations globally.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kehinde O, Ramsey LB, Gaedigk A, et al. Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens. Clin Pharmacol Ther. 2023. PMID: 36924260. doi:10.1002/cpt.2890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。